2-fluoro-N-propylaniline | 2806-10-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-fluoro-N-propylaniline
• 英文别名: 2-Fluor-N-propyl-anilin
• CAS: 2806-10-2
• 化学式: C₉H₁₂FN
• mdl: MFCD11145358
• 分子量: 153.199
• InChiKey: ADMJICSNKXQZOS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  光气 、 2-fluoro-N-propylaniline 生成
  参考文献：
  名称：

  FR2234293

  摘要：

  公开号：
• 作为产物：
  描述：

  三正丙胺 、 2-氟苯胺 在 palladium 10% on activated carbon 作用下， 以 甲苯 为溶剂， 反应 1.5h， 以31%的产率得到2-fluoro-N-propylaniline
  参考文献：
  名称：

  异质催化微波促进的苯胺与叔胺的选择性单N烷基化

  摘要：

  已经开发了在异质转移加氢条件下发生的钯催化的苯胺与叔胺的N-烷基化反应（参见方案）。该转氨协议使用相对便宜且易于回收的非均相催化剂，可以有效地应用于不同的底物，适用于大规模制备。

  DOI：

  10.1002/chem.201002704

文献信息

• [EN] OPTICALLY ACTIVE 1-(FLUORO-,TRIFLUOROMETHYL-OR TRIFLUOROMETHOXY-SUBSTITUTED PHENYL)ALKYLAMINE N-MONOALKYL DERIVATIVES AND PROCESS FOR PRODUCING SAME<br/>[FR] DERIVES DE 1-( PHENYLE A SUBSTITUTION FLUORO,TRIFLUOROMETHYLE OU TRIFLUOROMETHOXY)ALKYLAMINE N-MONOALKYLE OPTIQUEMENT ACTIFS ET LEUR PROCEDE DE PRODUCTION
  申请人：CENTRAL GLASS CO LTD

  公开号：WO2004022521A1

  公开（公告）日：2004-03-18

  An optically active 1-(fluoro-, trifluoromethyl- or trifluoromethoxy-substituted phenyl)alkylamine N-monoalkyl derivative represented by the formula [4] is produced by a process including (a) reacting an optically active secondary amine, represented by the formula [1], with an alkylation agent R2-X, in the presence of a base, thereby converting the secondary amine into an optically active tertiary amine represented by the formula [3]; and (b) subjecting the tertiary amine to a hydrogenolysis, thereby producing the N-monoalkyl derivative,wherein R represents a fluorine atom, trifluoromethyl group or trifluoromethoxy group, n represents an integer of from 1 to 5, each of R1 and R2 independently represents an alkyl group having a carbon atom number of from 1 to 6, Me represents a methyl group, Ar represents a phenyl group or 1- or 2-naphthyl group, * represents a chiral carbon, and X represents a leaving group.

  通过以下过程制备一种光学活性的1-(氟代、三氟甲基或三氟甲氧基取代的苯基)烷基胺N-单烷基衍生物，其化学式如下[4]：(a) 用碱存在下，将光学活性的二级胺（化学式[1]表示）与烷基化剂R2-X反应，从而将二级胺转化为光学活性的三级胺（化学式[3]表示）；(b) 将三级胺进行氢解作用，从而生成N-单烷基衍生物，其中R代表氟原子、三氟甲基基团或三氟甲氧基团，n代表1至5之间的整数，R1和R2分别代表具有1至6个碳原子的烷基基团，Me代表甲基基团，Ar代表苯基或1-或2-萘基，*代表一个手性碳，X代表一个离去基团。
• Opioid compounds
  申请人：Delta Pharmaceuticals, Inc.

  公开号：US05681830A1

  公开（公告）日：1997-10-28

  Diarylmethyl piperazine compounds having utility as exogenous receptor combinant species for binding with receptors such as delta, mu, sigma, and/or kappa receptors are disclosed. Compounds of the invention may be employed as conjugates in agonist/antagonist pairs for transductional monitoring and assays of neurotransmitter function, and also variously exhibit therapeutic utility, including mediating analgesia, and possessing utility for the treatment of diarrhea, urinary incontinence, mental illness, drug and alcohol addiction/overdose, lung edema, depression, asthma, emphysema, cough, and apnea, respiratory depression, cognitive disorders, emesis and gastrointestinal disorders.

  本发明揭示了具有作为外源受体结合物种与诸如δ、μ、σ和/或κ受体结合的效用的二苯甲基哌嗪化合物。该发明的化合物可以作为激动剂/拮抗剂对用于神经递质功能的转导监测和测定中的共轭物，并且还具有各种治疗效用，包括介导镇痛作用，并具有治疗腹泻、尿失禁、精神疾病、药物和酒精成瘾/过量、肺水肿、抑郁症、哮喘、肺气肿、咳嗽和呼吸暂停、呼吸抑制、认知障碍、呕吐和胃肠道疾病的效用。
• Opioid compounds and methods for using same
  申请人：Delta Pharmaceuticals, Inc.

  公开号：US05552404A1

  公开（公告）日：1996-09-03

  Diarylmethyl piperazine compounds having utility as exogenous receptor combinant species for binding with receptors such as delta, mu, sigma, and/or kappa receptors are disclosed. Compounds of the invention may be employed as conjugates in agonist/antagonist pairs for transductional monitoring and assays of neurotransmitter function, and also variously exhibit therapeutic utility, including mediating analgesia, and possessing utility for the treatment of diarrhea, urinary incontinence, mental illness, drug and alcohol addiction/overdose, lung edema, depression, asthma, emphysema, cough, and apnea, respiratory depression, cognitive disorders, emesis and gastrointestinal disorders.

  本发明公开了具有作为外源受体组合物种类的功能的二芳基甲基哌嗪化合物，用于与δ、μ、σ和/或κ受体等受体结合。本发明的化合物可以作为激动剂/拮抗剂对共轭体在神经递质功能的转导监测和测定中使用，并且还可以表现出各种治疗效用，包括介导镇痛作用，并具有治疗腹泻、尿失禁、精神疾病、药物和酒精成瘾/过量、肺水肿、抑郁症、哮喘、肺气肿、咳嗽和呼吸暂停、呼吸抑制、认知障碍、呕吐和胃肠道疾病的效用。
• Opioid compounds and methods for making therefor
  申请人：Delta Pharmaceuticals, Inc.

  公开号：US05574159A1

  公开（公告）日：1996-11-12

  Diarylmethyl piperazine compounds having utility as exogenous receptor combinant species for binding with receptors such as delta, mu, sigma, and/or kappa receptors are disclosed. Compounds of the invention may be employed as conjugates in agonist/antagonist pairs for transductional monitoring and assays of neurotransmitter function, and also variously exhibit therapeutic utility, including mediating analgesia, and possessing utility for the treatment of diarrhea, urinary incontinence, mental illness, drug and alcohol addiction/overdose, lung edema, depression, asthma, emphysema, cough, and apnea, respiratory depression, cognitive disorders, emesis and gastrointestinal disorders.

  本发明揭示了具有外源性受体结合物种功能的二芳甲基哌嗪化合物，用于与δ、μ、σ和/或κ受体结合。本发明的化合物可作为激动剂/拮抗剂对中的共轭物，在神经递质功能的传导监测和检测中使用，并且也具有各种治疗效用，包括介导镇痛，并具有治疗腹泻、尿失禁、精神疾病、药物和酒精成瘾/过量、肺水肿、抑郁症、哮喘、肺气肿、咳嗽和呼吸暂停、呼吸抑制、认知障碍、呕吐和胃肠疾病的功效。
• PIPERAZINE COMPOUNDS USED IN THERAPY
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0711289A1

  公开（公告）日：1996-05-15